zepbound and tirzepatide Zepbound® with Ivím Health's Weight Management Program Tirzepatide Zepbound® - Prefilled Pen

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth

Clinical trials combining these agents reported 35-40% discontinuation rates when both were dosed together

The Bile Acid TUDCA Increases Glucose-Induced Insulin Secretion via the cAMP/PKA Pathway in Pancreatic Beta Cells. Wilms, Britta, et al

Social anxiety in digital communication preferences

In the ATTAIN-1 trial, participants achieved a mean weight loss of 12.4% over 72 weeks. Foundayo is not yet approved or available in the UK

Adverse events were mild and primarily gastrointestinal, such as nausea and constipation, occurring in 42% of participants